Interim Commercial Director
for rare disease launches in Benelux
RareGenetics provides senior commercial leadership on demand for orphan drug and rare disease launches — as interim Commercial Director, outsourced CCO, or Head of Launch — with deep Benelux and European rare-disease execution experience. Founded in Belgium in 2015 and led by Tom Meuleman.
Why this role is different in rare disease
Rare disease launches need relationship-driven specialty selling, tight KOL networks, pricing/payer negotiation and purpose-built distribution — not a scaled-down primary-care commercial model. Interim leadership must already know that playbook.
For the full launch scope — go-to-market, pricing, market access and distribution — see orphan drug launch in Europe.
Senior commercial leadership on demand
Interim or fractional commercial leadership for orphan drug and rare disease launches, from first commercial hire to launch execution.
Interim commercial leadership
- Outsourced CCO / Commercial Director engagement
- Head of Launch or commercial build-out for startups entering rare disease
- Board and C-suite advisory on rare disease commercial strategy
Launch team and go-to-market
- Launch team formation and coaching
- Go-to-market, specialty sales model, patient support programme oversight
Pricing, distribution and early access
- Pricing and payer negotiation support; coordination with market-access partners where needed
- Distribution pathway and early-access (NPP / compassionate use / medical need) setup support
Where: Benelux and wider Europe
Belgium, Netherlands, Luxembourg and wider Europe (France, Germany, UK, Nordics, Southern Europe, Switzerland, Austria; US/Middle East on request).
Tom Meuleman, Founder & Principal Consultant
23+ years rare disease commercial sales and marketing, (pre-)launch execution, distribution, lobbying and pricing negotiations. Track record alongside BioMarin, Amicus Therapeutics, CSL, Vifor Pharma, HRA Pharma, UCB, Enobia Pharma, Clementia Pharmaceuticals and Prosensa Therapeutics.
How engagements work
Scoped interim or fractional mandate (weeks to months), clear deliverables, option to request client references before kick-off. Contact: tom.meuleman@raregenetics.be · +32 477 89 60 40.
Frequently asked questions
Can RareGenetics act as our interim Commercial Director?
Yes. RareGenetics provides interim and outsourced commercial leadership for rare disease and orphan drug launches: as outsourced CCO or Commercial Director, or as Head of Launch.
Do you work only in Benelux or across Europe?
RareGenetics is based in Belgium with a Benelux focus (Belgium, the Netherlands and Luxembourg) and Europe-wide coverage, including France, Germany, the UK, the Nordics, Southern Europe, Switzerland and Austria. The US and the Middle East are available on request.
Is this a pure market access service?
No. The focus is commercial launch leadership. Where market access work is needed, RareGenetics coordinates with market-access partners.
How do we start an interim engagement?
Email tom.meuleman@raregenetics.be or call +32 477 89 60 40. Engagements are scoped interim or fractional mandates with clear deliverables, and client references are available on request before kick-off.
Need an interim Commercial Director? Let's talk.
Scoped interim or fractional mandate (weeks to months), clear deliverables, option to request client references before kick-off. Contact Tom Meuleman directly: tom.meuleman@raregenetics.be · +32 477 89 60 40.
-
Phone+32 477 89 60 40
-
LinkedInlinkedin.com/in/meulemat
Tom Meuleman · Founder & Principal Consultant · Belgium (Europe-wide coverage)